BiotechTube

Ofatumumab

ApprovedCompleted
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Leukaemia, Lymphocytic, Chronic

Conditions

Leukaemia, Lymphocytic, Chronic

Trial Timeline

Jan 1, 2009 → May 1, 2013

NCT ID
NCT00802737

About Ofatumumab

Ofatumumab is a approved stage product being developed by Genmab for Leukaemia, Lymphocytic, Chronic. The current trial status is completed. This product is registered under clinical trial identifier NCT00802737. Target conditions include Leukaemia, Lymphocytic, Chronic.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00802737ApprovedCompleted

Competing Products

20 competing products in Leukaemia, Lymphocytic, Chronic

See all competitors
ProductCompanyStageHype Score
AZD3632 + PosaconazoleAstraZenecaPhase 1/2
41
AZD1152 + C14 AZD1152AstraZenecaPhase 1
33
AcalabrutinibAstraZenecaApproved
85
AZD2811 + Azacitidine + VenetoclaxAstraZenecaPhase 1
33
Administration of AZD6738AstraZenecaPhase 1
33
AZD1152AstraZenecaPhase 1
33
AZD0486 + Prednisone (or equivalent) + Rituximab + Cyclophosphamide + Vincristine + Doxorubicin + AcalabrutinibAstraZenecaPhase 1/2
41
AZD2171AstraZenecaPhase 1
33
Nilotinib, Pegylated interferon alpha-2b, ImatinibMerckPhase 2
52
chlorambucil, tablets + ofatumumab (GSK1841157) infusionNovartisPhase 3
77
Ofatumumab + Physicians' ChoiceNovartisPhase 3
77
OFC Infusion + FC infusionNovartisPhase 3
77
NilotinibNovartisPhase 3
77
OfatumumabNovartisPhase 3
77
Daunorubicin + Cytarabine + Eltrombopag + PlaceboNovartisPhase 2
52
BlinatumomabAmgenPhase 1
32
Idelalisib + RituximabGilead SciencesPre-clinical
22
humanised monoclonal antibody, veltuzumab + humanised monoclonal antibody epratuzumab + humanised monoclonal antibodies veltuzumab and epratuzumabGilead SciencesPhase 1/2
40
BosulifPfizerPhase 2
51
Bosutinib + Imatinib + Nilotinib + Dasatinib + PonatinibPfizerPre-clinical
22

Other Products from Genmab

ZalutumumabPhase 3
74
Rina-S + BevacizumabPhase 3
74
Epcoritamab + Cyclophosphamide + Rituximab + Vincristine + Doxorubicin + PrednisonePhase 3
74
Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + GemcitabinePhase 3
74
Acasunlimab + Pembrolizumab + DocetaxelPhase 3
74